TickerStar monitors official filings, investor releases, earnings, and call updates for RVMD. Subscribe to RVMD alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.
RVMD filed its 10-Q; the most relevant disclosure change is added Product revenue recognition: Company began recognizing net product revenue from RASONQUE in Q3 2026 following FDA approval in August 2026, recording $197.6 million in product revenue, net for the three and nine months ended September 30, 2026. Revenue is recognized at the transaction pric. Customer concentration: Customer A represented 71% of net_sales; Customer B represented 28% of net_sales.
On October 8, 2026, Revolution Medicines drew the $250.0 million Tranche A under its $750.0 million senior secured term loan facility with Royalty Pharma Development Funding, LLC, triggered by FDA approval of RASONQUE™ (daraxonrasib) for metastatic pancreatic adenocarcinoma. The company paid a $5.0 million draw fee; up to $500.0 million of additional capacity remains available under the Loan Agreement subject to milestones and conditions. The company elected not to exercise the Tranche 3 option under its separat...
Revolution Medicines disclosed that on August 26, 2026, the U.S. FDA approved RASONQUE™ (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The approval was based on data from the global, randomized Phase 3 RASolute 302 trial evaluating RASONQUE versus investigator's choice of cytotoxic chemotherapy in previously treated metastatic pancreatic adenocarcinoma. On...
FY2026 GAAP operating expenses was raised by +$400.0M to $2.1 billion to $2.2 billion (midpoint $2.15 billion). The company reported a Q2 2026 net loss of $644.4 million versus a $247.8 million net loss in Q2 2025, including a $151.0 million non-cash charge tied to the fair value of EQRx acquisition warrants. Cash, cash equivalents and marketable securities stood at $3.9 billion as of June 30, 2026, reflecting April 2026 concurrent equity and convertible notes offerings totaling $2.225 billion in gross proceeds...
RVMD filed its 10-Q; the most relevant disclosure change is added Convertible senior notes: New Note 10 discloses $500.0 million aggregate principal of 0.50% Convertible Senior Notes due 2033 issued April 17, 2026 with $487.4 million net carrying value, 5.0302 share per $1,000 conversion rate, $198.80 initial conversion price, and estimated fair valu.